Wall Street analyst estimates for Genelux Corporation (GNLX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer.
Valuation Ratios
| Price / Book | 5.99 |
| EV / EBITDA | -3.00 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $11.1M | $170000 | $8000 | $8000 |
| Cost of Revenue | 0 | $658000 | $895000 | $968000 | $1.0M | $903000 | $574000 |
| Gross Profit | 0 | -$658000 | -$895000 | $10.1M | -$848000 | -$895000 | -$566000 |
| Research & Development | $7.5M | $6.2M | $6.3M | $9.1M | $12.8M | $19.0M | $19.9M |
| Selling, General & Admin | $3.3M | $6.2M | $8.3M | $5.0M | $11.6M | $12.7M | $13.4M |
| Operating Expenses | $10.9M | $11.8M | $13.7M | $13.1M | $23.3M | $30.8M | $32.6M |
| Operating Income | -$10.9M | -$12.4M | -$14.6M | -$3.0M | -$24.2M | -$31.7M | -$33.2M |
| EBITDA | -$10.5M | -$11.8M | -$13.7M | -$1.7M | -$26.5M | -$29.0M | -$31.6M |
| Interest Expense | $761000 | $1.2M | $1.8M | $1.4M | $4.0M | 0 | 0 |
| Pre-tax Income | -$11.6M | -$13.6M | -$16.4M | -$4.1M | -$28.3M | -$29.9M | -$32.1M |
| Income Tax | 0 | 0 | 0 | $1.1M | 0 | 0 | 0 |
| Net Income | -$11.6M | -$14.9M | -$17.8M | -$5.2M | -$28.3M | -$29.9M | -$32.1M |
| EPS | $-0.49 | $-0.58 | $-0.69 | $-0.21 | $-1.16 | $-0.95 | $-0.86 |
| EPS (Diluted) | $-0.49 | $-0.58 | $-0.69 | $-0.21 | $-1.16 | $-0.95 | $-0.86 |
| Shares Outstanding (Diluted) | $23.6M | $23.6M | $23.6M | $24.6M | $24.4M | $31.5M | $37.2M |
Price
| Price | $2.34 |
| Market Cap | $105M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACIU · ALDX · CADL · CLLS · CTNM · DRTS · LXEO
Explore sector: Healthcare · Biotechnology
More sections of GNLX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks